智通财经网·2025-12-08 09:40Core Viewpoint - Shanghai Pharmaceuticals has successfully included its amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective January 1, 2026, which is expected to enhance market share and competitiveness [1] Group 1: Company Information - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has obtained the listing rights for amisulpride orally disintegrating tablets [1] - The amisulpride orally disintegrating tablets are a modified formulation of the amisulpride tablets launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched amisulpride orally disintegrating tablets [1] Group 2: Market Impact - The inclusion of amisulpride orally disintegrating tablets in the National Medical Insurance Directory is expected to expand the product's market share and improve its competitive position [1] - According to the IQVIA database, the hospital procurement amount for amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1] - The successful negotiation for inclusion in the insurance directory will provide valuable experience for the company in promoting other products [1]